Getting your child to exercise may be a difficult task. Nautilus Sports and Fitness wants to change that with a new program designed with your child in mind. The best part about it? Parents can leave their child in the hands of each instructor knowing they are safe.
For more information on this summer program click on the link.
It’s not unusual for people to say they feel much better after dropping gluten from their diet, even though they don't have celiac disease, digestive experts report.
There's still time to get vaccinated for current flu season, health officials say
The holidays are a time for flavorful food. And with this menu from WebMD, you can keep your calories in check.
Ready to raise a glass for the holidays without raising your calories? From eggnog to a 70-calorie cosmo, WebMD can make it light, festive, and still enjoyable.
These vacation and travel tips will help people with bladder control issues enjoy, instead of dread, their next trip.
Welcome to Ask Healthy Living -- in which you submit your most burning health questions and we do our best to ask the experts and get back to you. Get in touch here and you could appear on Healthy Living! "Ask Healthy Living" is for informational purposes only and is not a substitute for medical advice. Please consult a qualified health care professional for personalized medical advice.
Women with an especially deadly type of breast cancer who received a treatment regimen containing an experimental AbbVie Inc drug prior to surgery are likely to have a significantly better response than those who get a standard chemotherapy regimen, according to data from a clinical trial. Patients with so-called triple negative breast cancer, who tend to be younger and have a very poor prognosis, appeared to have double the response rate to the regimen containing AbbVie's veliparib in a new type of study that exploits advances in molecular understanding of the disease, researchers found. This type of trial should help companies select the right group of patients to enroll into larger, more traditional late stage clinical trials, potentially cutting the cost of bringing new medicines to market. "It's a very nimble trial design that allows you to enroll a fairly small number of patients and come to a fairly high certainty of success (in later larger trials) in a specific subset of patients," explained Dr. Hope Rugo, who presented the data at the San Antonio Breast Cancer Symposium on Friday.